Continuum Advisory LLC Makes New $546,000 Investment in Boston Scientific Corporation $BSX

Posted by George Bondi on Sep 5th, 2026

Boston Scientific logo Continuum Advisory LLC purchased a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) during the 2nd quarter, Holdings Channel reports. The firm purchased 12,796 shares of the medical equipment provider’s stock, valued at approximately $546,000.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. CYBER HORNET ETFs LLC grew its stake in shares of Boston Scientific by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after purchasing an additional 132 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management grew its position in Boston Scientific by 4.7% in the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock valued at $294,000 after buying an additional 139 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its stake in Boston Scientific by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock valued at $4,516,000 after buying an additional 140 shares during the period. Kingsview Wealth Management LLC lifted its stake in shares of Boston Scientific by 2.4% in the 4th quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock worth $578,000 after acquiring an additional 142 shares during the period. Finally, RiverFront Investment Group LLC lifted its stake in shares of Boston Scientific by 0.7% in the 4th quarter. RiverFront Investment Group LLC now owns 21,308 shares of the medical equipment provider’s stock worth $2,032,000 after acquiring an additional 150 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Trading Up 1.9%

NYSE:BSX opened at $47.85 on Friday. The stock has a fifty day simple moving average of $46.90 and a 200 day simple moving average of $55.74. The firm has a market capitalization of $69.35 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 1.09 and a beta of 0.57. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the company earned $0.75 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has initiated a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Jefferies Financial Group lowered their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Barclays decreased their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. UBS Group cut their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Mizuho decreased their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $71.62.

Check Out Our Latest Research Report on BSX

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific’s ICVT Business Gains Momentum
Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.